Belharra Therapeutics

Belharra Therapeutics is a biotechnology startup founded in 2021, headquartered in the United States, with its primary lab and offices in San Diego, California. The company's slogan "Redefining UnDruggable" reflects its ambition to revolutionize the drug discovery paradigm. Their proprietary photoaffinity-based chemoproteomics platform has attracted significant attention due to its capability to identify novel starting points for transformative medicines, targeting previously untreatable diseases and conditions. The company's key innovation lies in its next-generation chemoproteomics platform, which enables the identification of small molecule drug candidates for any binding site, on any protein, in any conformational state, in any cell type. Belharra was founded by Christopher G. Parker, Ph.D. and John Teijaro, Ph.D., who are pioneers in the field of chemical biology, along with serial biotech founders Benjamin Cravatt, Ph.D. and Stuart Schreiber, Ph.D. In January 2023, Belharra Therapeutics secured a significant $50 million Series A investment from Versant Ventures, indicating strong investor confidence in the company's potential. This investment not only provides substantial financial backing but also signifies validation from a reputable venture capital firm. Overall, Belharra Therapeutics is well-positioned to make a significant impact in the biotechnology industry with its disruptive approach to drug discovery.